Effect of interleukin-2 on long term infusion treatment regimen of ch14.18/CHO antibody on activity in relapsed/refractory neuroblastoma patients.

被引：0
|
作者：
Loibner, Hans
Siebert, Nikolai
Eger, Christin
Janzek, Evelyne
Ladenstein, Ruth
Lode, Holger N.
机构：
[1] Apeiron Biol AG, Vienna, Austria
[2] Univ Med Greifswald, Greifswald, Germany
[3] Apeiron Biol, Vienna, Austria
[4] St Anna Childrens Hosp & Res Inst, Paediat Haematol Oncol, SIOP Europe Neuroblastoma Grp, Vienna, Austria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.10563
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10563
引用
收藏
页数：2
相关论文
共 47 条
  • [21] Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy
    Simon, Thorsten
    Hero, Barbara
    Faldum, Andreas
    Handgretinger, Rupert
    Schrappe, Martin
    Klingebiel, Thomas
    Berthold, Frank
    BMC CANCER, 2011, 11
  • [22] Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy
    Thorsten Simon
    Barbara Hero
    Andreas Faldum
    Rupert Handgretinger
    Martin Schrappe
    Thomas Klingebiel
    Frank Berthold
    BMC Cancer, 11
  • [23] Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab
    Siebert, Nikolai
    Seidel, Diana
    Eger, Christin
    Brackrock, Diana
    Reker, Daniel
    Schmidt, Manuela
    Lode, Holger N.
    JOURNAL OF IMMUNOLOGICAL METHODS, 2013, 398 : 51 - 59
  • [24] Functional Bioassays for Immune Monitoring of High-Risk Neuroblastoma Patients Treated with ch14.18/CHO Anti-GD2 Antibody
    Siebert, Nikolai
    Seidel, Diana
    Eger, Christin
    Juettner, Madlen
    Lode, Holger N.
    PLOS ONE, 2014, 9 (09):
  • [25] Immunological long-term follow-up of neuroblastoma stage IV patients after anti-GD2 CH14.18 antibody treatment.
    Kayser, Simone
    Icheva, Vanya
    Stevanovic, Stefan
    Siebert, Nikolai
    Feucht, Judith
    Lode, Holger N.
    Handgretinger, Rupert
    Feuchtinger, Tobias
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] Survival of Neuroblastoma Patients Treated by Long-Term Infusion of Anti-GD2 Antibody CH14.18/CHO Correlate with Killer-Cell Ig-Like Receptor (KIR) Genotypes and Fcγ-Receptor Polymorphisms
    Lode, H.
    Troschke-Meurer, S.
    Valteau-Couanet, D.
    Garaventa, A.
    Gray, J.
    Castel, V.
    Yaniv, I.
    Siebert, N.
    Eger, C.
    Juettner, M.
    Kietz, S.
    Karoline, E.
    Janzek, E.
    Loibner, H.
    Mueller, I.
    Ladenstein, R.
    PEDIATRIC BLOOD & CANCER, 2016, 63 : S39 - S39
  • [27] Survival of neuroblastoma patients treated by long-term infusion of anti-GD2 antibody ch14.18/CHO and killer-cell Ig-like receptor (KIR) genotypes and Fcγ-receptor polymorphisms.
    Lode, Holger N.
    Loibner, Hans
    Troschke-Meurer, Sascha
    Couanet, Dominique Valteau
    Garaventa, Alberto
    Gray, Juliet
    Castel, Victoria
    Yaniv, Isaac
    Siebert, Nikolai
    Eger, Christin
    Juettner, Madlen
    Kietz, Silke
    Ehlert, Karoline
    Janzek, Evelyne
    Mueller, Ina
    Ladenstein, Ruth
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)
  • [28] SHORT (STI) AND LONG TERM INFUSION (LTI) OF CH14.18/CHO IMMUNOTHERAPY: TOXICITY PROFILES AND OUTCOMES IN 530 HIGH RISK NEUROBLASTOMA (HR-NBL) PATIENTS IN TWO SIOPEN TRIALS
    Ladenstein, R.
    Poetschger, U.
    Gray, J.
    Couanet, D. Valteau
    Luksch, R.
    Castel, V.
    Yaniv, I.
    Laureys, G.
    Elliott, M.
    Michon, J.
    Owens, C.
    Trahair, T.
    Chan, G. Chi Fung
    Ruud, E.
    Schroeder, H.
    Popovic, M. Beck
    Glogova, E.
    Schreier, G.
    Loibner, H.
    Lode, H.
    PEDIATRIC BLOOD & CANCER, 2015, 62 : S145 - S145
  • [29] Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma
    Brian S. Choi
    Paul M. Sondel
    Jacquelyn A. Hank
    Heidi Schalch
    Jacek Gan
    David M. King
    Kari Kendra
    David Mahvi
    Li-Yin Lee
    KyungMann Kim
    Mark R. Albertini
    Cancer Immunology, Immunotherapy, 2006, 55 : 761 - 774
  • [30] Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma
    Choi, B
    Sondel, PM
    Hank, JA
    Schalch, H
    Gan, J
    King, DM
    Kendra, K
    Mahvi, D
    Lee, LY
    Kim, KM
    Albertini, MR
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (07) : 761 - 774
12345